Concept of personalized regenerative approaches
Autologous Regenerative Therapy is described as an innovative medical discipline that aims to regenerate injured tissues or stimulate their repair using the patient’s own cells within a single medical procedure. This approach applies the same natural principles of tissue engineering through an easy, reproducible, and relatively fast protocol, with particular emphasis on the use of autologous mesenchymal stem cells (MSCs) derived from adipose tissue. In osteoarthritis, where intrinsic healing capacity is limited by poor vascularization and restricted access to progenitor cells, such autologous strategies are positioned as a means to support tissue repair rather than merely palliate symptoms.
Human adipose tissue has been characterized as a source of multipotent mesenchymal stromal cells similar to those found in bone marrow, giving rise to adipose-derived stem or stromal cells (ADSCs/ASCs) located predominantly in the stromal vascular fraction. These cells can differentiate into multiple mesenchymal lineages, including adipocytes, chondrocytes, osteogenic cells, myocytes, hepatocytes, and endothelial cells, and they secrete bioactive molecules with angiogenic, antifibrotic, antiapoptotic, and immunomodulatory properties. This combination of differentiation potential and paracrine activity underpins the rationale for using autologous adipose tissue as a regenerative tool in musculoskeletal and soft-tissue disorders.
In clinical practice, autologous micro-fragmented adipose tissue is used as a naturally enriched source of stromal vascular fraction cells and mesenchymal stem cells, obtained through minimally invasive harvesting and minimal manipulation. Devices based on the Superficial Enhanced Fluid Fat Injection concept are designed to collect highly fluid adipose clusters from the superficial adipose tissue, which is reported to contain higher concentrations of mesenchymal and vascular stem cells. The harvested tissue can be injected directly without further processing, providing a standardized way to deliver regenerative cell populations in a single session.
Personalized regenerative medicine in this context is closely linked to the use of autologous tissue that inherently reflects the patient’s own biological milieu. Clinical series of patients with hip and knee osteoarthritis treated with intra-articular injection of autologous fat micrograft illustrate how such therapies can be integrated into individualized management pathways. These procedures are performed under local anesthesia, with tailored volumes and target joints, and are followed by structured clinical follow-up to monitor pain, range of motion, stiffness, and patient-reported outcomes over time.
Biological heterogeneity among patients
Biological heterogeneity is evident at the level of disease expression in osteoarthritis, where risk factors such as age, heredity, lifestyle, obesity, and local biomechanical conditions contribute to variable patterns of joint degeneration and clinical disability. Patients typically present with differing degrees of pain, swelling, stiffness, and functional limitation, and radiographic grading systems such as Kellgren–Lawrence for the knee and Tönnis for the hip capture this variability in structural damage. In a cohort treated with autologous fat micrograft, patients ranged from early to moderate radiographic stages, reflecting a spectrum of joint pathology within which regenerative interventions are applied.
Heterogeneity also emerges in clinical response to autologous regenerative therapy. In an observational series of hip and knee osteoarthritis, the best outcomes in terms of pain reduction and improved joint performance were observed in younger patients with lower osteoarthritis grades at baseline. Conversely, older patients and those with more severe radiographic disease showed less improvement in mobility, although a reduction in pain was still reported. These findings suggest that pre-existing joint status and patient characteristics influence the magnitude and profile of response to autologous adipose-derived stromal vascular fraction.
Sex-related differences further illustrate biological and behavioral heterogeneity. In the same cohort, women represented a higher proportion of treated patients and were reported to achieve better clinical results, with a lower percentage proceeding to joint replacement during follow-up. The authors hypothesized that this may relate not only to biological factors but also to differences in adherence to conservative measures such as weight control, use of supplements, and physiotherapy, which can modulate the overall therapeutic context in which regenerative treatments are delivered.
At the tissue level, adipose-derived stromal cells exhibit conserved mesenchymal properties across donors, including the ability to differentiate towards osteogenic, chondrogenic, and adipogenic lineages and to secrete factors involved in angiogenesis and immunomodulation. Nonetheless, studies emphasize that harvesting technique, cannula design, and tissue compartment (such as superficial adipose tissue) can influence cell yield, viability, and composition of the stromal vascular fraction. These technical variables interact with patient-specific adipose tissue characteristics, adding another layer of heterogeneity that may affect the regenerative potential of autologous grafts.
Matching therapy to patient-specific profiles
Matching autologous regenerative therapy to patient-specific profiles begins with appropriate selection of candidates based on clinical and radiographic criteria. In the reported experience with intra-articular fat micrograft, inclusion criteria encompassed men and women aged 20 to 80 years with hip or knee pain and initial-stage degenerative osteoarthritis, as defined by established grading systems. This focus on mild to moderate disease reflects an attempt to align the biological capacity for regeneration with the structural integrity of the joint, favoring patients in whom residual cartilage and joint architecture may still respond to the trophic and reparative effects of adipose-derived stromal cells.
The procedural approach itself is tailored to the individual joint and clinical scenario. The Sefficare device integrates a guided harvesting cannula designed to collect micro-fragmented adipose tissue from the superficial adipose layer at a standardized depth, with the aim of maximizing the content of mesenchymal and vascular stem cells while minimizing trauma. The harvested volume and the choice of injection site (knee or hip, unilateral or bilateral) are determined according to the patient’s symptomatic joints and radiologic findings, allowing the regenerative intervention to be directed to the specific anatomical targets most responsible for disability.
Post-treatment evaluation is structured to capture individual trajectories of response. Patients undergo serial assessments at 3, 6, and 12 months, including measurement of range of motion, evaluation of stiffness and functional tasks such as rising from a chair and walking, and completion of validated pain scales and health-related quality-of-life questionnaires. This follow-up framework enables clinicians to observe how each patient’s pain, mobility, and perceived health evolve over time after autologous therapy, and to relate these changes to baseline characteristics such as age and osteoarthritis grade.
Observational data suggest that patients with less advanced osteoarthritis and younger age derive greater improvements in joint function, while even those with more severe disease may experience meaningful pain reduction. These patterns support a pragmatic matching of autologous adipose-derived stromal vascular fraction therapy to patient profiles where the goal may range from delaying joint replacement and preserving function in early disease to primarily alleviating pain in more advanced stages or in individuals who decline surgery. Such stratification remains empirical and underscores the need for further studies to refine predictive factors and optimize patient selection.
Targeted indications and treatment planning
The principal indication described for autologous micro-fragmented adipose tissue therapy is symptomatic osteoarthritis of weight-bearing joints, particularly the knee and hip. Osteoarthritis is characterized by progressive articular cartilage loss, joint pain, stiffness, and functional decline, and conventional conservative treatments—such as physical therapy, weight loss, pharmacologic agents, steroid injections, and intra-articular hyaluronic acid—do not reverse the degenerative process. In this context, intra-articular injection of adipose-derived stromal vascular fraction is proposed as a regenerative option that may address underlying tissue damage while also improving symptoms.
In the reported series, 250 patients were treated with the Sefficare device, with 190 procedures involving the knees and 60 involving the hips. The mean age at treatment was 52.4 years, and all procedures targeted joints with radiographically confirmed early-stage osteoarthritis. Treatment planning included decisions on unilateral versus bilateral injections, with bilateral knee procedures performed when both joints exhibited comparable pathology. This distribution reflects a focus on joints where mechanical load and degenerative changes are prominent and where joint replacement is often the eventual endpoint of disease progression.
The technical planning of the procedure emphasizes minimal invasiveness and preservation of cell viability. Adipose tissue is harvested using a syringe-based system with low negative pressure, washed by decantation rather than centrifugation, and minimally exposed to ambient air. Evidence from comparative studies indicates that such minimally manipulated micro-fragmented adipose tissue contains viable and metabolically active cells, with cell viability comparable to that obtained by enzymatic digestion of liposuction aspirate. This supports the use of mechanically processed autologous tissue as a practical and regulatory-aligned source for regenerative applications.
Clinical outcomes inform ongoing treatment planning and expectations. In the osteoarthritis cohort, an average increase of approximately 10 degrees in joint range of motion was observed three months after treatment, accompanied by reduced stiffness and a progressive decrease in pain scores, with the most pronounced pain relief at six months for the knee and between six and twelve months for the hip. At one year, 85% of patients reported satisfaction with the procedure and improvements in pain and quality of life, and only a small proportion proceeded to joint replacement within five years. These data suggest that autologous adipose-derived stromal vascular fraction therapy can be integrated into long-term management strategies aimed at symptom control and potential delay of major surgery in selected patients.
Role of diagnostics in personalization
Diagnostic imaging plays a central role in personalizing autologous regenerative therapy for osteoarthritis. Before treatment, all patients in the described series underwent radiographs and magnetic resonance imaging of the symptomatic hip or knee to evaluate and grade osteoarthritis severity. Radiographic grading using the Kellgren–Lawrence scale for the knee and the Tönnis scale for the hip provided standardized measures of joint degeneration, which were used both for inclusion criteria and for stratifying patients according to disease stage. This imaging-based characterization ensures that autologous therapy is directed to joints with structural features compatible with the intended regenerative mechanism.
Clinical assessment complements imaging in defining the baseline status and guiding expectations. Prior to injection, patients were evaluated for joint pain and mobility, including detailed measurement of range of motion and assessment of stiffness and functional tasks such as rising from a chair and walking a short distance. Pain intensity was quantified using a 10-point Visual Analogue Scale, and health-related quality of life was assessed with the SF-12 questionnaire. These diagnostic tools provide a multidimensional profile of each patient’s symptoms and functional limitations, which can be tracked over time to evaluate individual responses to autologous therapy.
The choice of harvesting site and technique is also informed by anatomical and histological considerations. The guided cannula system is designed to sample superficial adipose tissue at a depth of approximately 15 mm, a compartment reported to contain higher densities of mesenchymal and vascular stem cells. By standardizing the depth and plane of harvesting, the device aims to reduce variability in the cellular composition of the graft, thereby contributing to a more predictable regenerative product across patients. This technical standardization is a form of procedural personalization, aligning the harvested tissue characteristics with the biological requirements of the target indication.
Post-treatment diagnostics are essential for monitoring safety and efficacy at the individual level. Follow-up visits at 3, 6, and 12 months include repeated pain scoring, range-of-motion measurements, and functional assessments, as well as repeat SF-12 questionnaires at one year. These data allow clinicians to identify patterns such as early improvements in mobility and stiffness, followed by more gradual reductions in pain, and to relate these trajectories to baseline imaging and clinical findings. Although repeat radiographs were not routinely performed in the reported series, the combination of clinical and patient-reported outcomes provides a practical framework for evaluating personalized responses to autologous regenerative interventions.
Challenges and future perspectives
Despite encouraging results, several challenges limit the current application of autologous adipose-derived regenerative therapies. The osteoarthritis study was retrospective and lacked a control group, and the number of cases, while substantial, remains modest for definitive conclusions. The authors highlight that clinical outcomes are variable and not yet predictable, even though treatment appears safe and associated with low complication rates. This variability underscores the need for more rigorous prospective studies to clarify which patient subgroups benefit most and to quantify the magnitude and durability of effects.
Another challenge lies in standardizing tissue harvesting and processing while complying with regulatory constraints. Enzymatic digestion of adipose tissue with collagenase is considered a gold-standard method for isolating stromal vascular fraction but is subject to regulatory limitations in some jurisdictions. Comparative research has shown that micro-fragmented adipose tissue harvested with small-port cannulas and processed without enzymes can yield viable and proliferative cells with metabolic activity comparable to enzymatically derived stromal vascular fraction. These findings support the feasibility of minimal manipulation approaches but also point to the need for continued quality control and characterization of the cellular products used in clinical practice.
From a clinical perspective, integrating autologous regenerative therapies into treatment algorithms for osteoarthritis requires careful positioning relative to established conservative measures and surgical options. Observational data suggest that intra-articular fat micrograft may improve pain and function and potentially delay the need for joint replacement in patients with mild to moderate disease or in those who decline surgery. However, the absence of randomized controlled comparisons and the influence of concomitant therapies such as physiotherapy and lifestyle modification complicate the interpretation of outcomes. Future work should aim to define standardized protocols, comparative effectiveness, and cost implications within broader musculoskeletal care pathways.
Looking ahead, advances in analytical technologies and cell biology may enhance the personalization of autologous regenerative medicine. Techniques such as non-invasive fractionation and characterization of adipose tissue and stromal cells have already been applied to evaluate sample fluidity, cellular composition, and stemness properties in aesthetic and reconstructive contexts. Extending such approaches to orthopedic indications could facilitate more precise profiling of grafts and their relationship to clinical outcomes. Alongside larger, controlled clinical trials, these developments may contribute to refining patient selection, optimizing harvesting and injection strategies, and ultimately improving the predictability and effectiveness of autologous therapies in personalized regenerative medicine.
Sources (Bibliography)
- Trentani P, Meredi E, Zarantonello P, Gennai A. Role of Autologous Micro-Fragmented Adipose Tissue in Osteoarthritis Treatment. Journal of Personalized Medicine, 2024.
- Gennai A, Bovani B, Colli M, et al. Comparison of Harvesting and Processing Technique for Adipose Tissue Graft: Evaluation of Cell Viability. International Journal of Regenerative Medicine, 2021.
- Alviano F, Roda B, Rossi M, et al. Characterization of Tissue and Stromal Cells for Facial Aging Treatment. Aesthetic Surgery Journal, 2020.